Dysmenorrhea. primary dysmenorrhea
Conditions
Interventions
Intervention 1: In one of the groups in 2th cycle with onset of menstrual pain, participant use 1 tab of celecoxib 200 mg every 12h and in 3th cycle she should a tab of ibuprofen 400mg every 6-8h then
Treatment - Drugs
In one of the groups in 2th cycle with onset of menstrual pain, participant use 1 tab of celecoxib 200 mg every 12h and in 3th cycle she should a tab of ibuprofen 400mg every 6-8h then she fill the qu
In another group in 2th cycle with onset of pain the participants use 1 tab of ibuprofen 400mg every 6-8h and in 3th cycle 1 tab of celecoxib 200 mg every 12h, the questionnaire No:2 will be filled.
Sponsors
Ilam university of medical sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 22 Years
Inclusion criteria
Inclusion criteria: This is double-blinded crossing trial that will be perform in two dormatorse(khayam and kawsar) of students affiliated to ilam university of medical science. The aim of study is to survay the effect of celecoxib and iboprofen on primary dysmenorrhea in 80 girl students. Inclusion criteria including age 18-22 y-o, presence of menstrual pains among recent 6 month. Exclusion criteria including history of abdomenal/ pelvic surgery and usage of OCPs. The samples will be select by convenience method then assigned to two groups of celecoxib – ibuprofen and celecoxib – ibuprofen. Each of participants evaluated for 3 menstrual cycles. That in first we take no intervention and the participant should record its pain severity and duration with Andrish-Melisum, VAS scale and a watch. In one of the groups in 2th cycle with onset of menstrual pain, participant use 1 tab of celecoxib 200 mg every 12h and in 3th cycle she should a tab of ibuprofen 400mg every 6-8h then she fill the questionnaire No:2. In another group in 2th cycle with onset of pain the participants use 1 tab of ibuprofen 400mg every 6-8h and in 3th cycle 1 tab of celecoxib 200 mg every 12h, the questionnaire No:2 will be filled.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intensity of menstural pain. Timepoint: befor and 1,2,3,4,6,8,12,24,48 and 72 hour after intervention. Method of measurement: VAS scale.;Duration of menstural pain. Timepoint: onset of pain to stop. Method of measurement: watch. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZainab suhrabi
Ilam university of medical sciences
Outcome results
None listed